E OncoSec Raising Its Profile In Fight Against Cancer

OncoSec Medical (ONCS) is a biotechnology company based out of San Diego, California. It harnesses the body’s own immune system to fight off and kill cancer. The company accomplishes this through its ImmunoPulse IL-12 technology. This type of technology helps the company to boost local delivery and enhance the uptake of DNA based therapeutics.

IL-12 is a protein that is naturally produced by the immune system. The company has achieved good results with ImmunoPulse IL-12 as a monotherapy approach. In addition, it is a promising time for the company because it recognizes the potential to increase response rates for patients with Melanoma. It achieves this by combining its technology with an already approved immunotherapy drug by the name of Keytruda (pembrolizumab). Keytruda is an immunotherapy drug produced and marketed by Merck & Co. (MRK).

Immune-Cell Numbers Predict Response to Combination Immunotherapy in Melanoma

Combination Approach

The human body can’t fight off cancer cells because the immune system is unable to recognize them. Cancer cells have a protective mechanism that masks them from the immune system. That means T-cells can’t kill these cancerous cells, because it can’t find them. Keytruda is a type of antibody that blocks the protective mechanism of cancer cells.  Keytruda is an anti PD-1 immunotherapy drug. It targets the programmed cell death 1 receptor. (PD-1 is a cell surface receptor that acts as the cancer cell’s bodyguard. It is responsible for eliminating T-cell activity by lowering the immune system’s response.)

This is where OncoSec’s technology has a chance to come in and boost efficacy in patients with melanoma. Current treatments for melanoma such as Bristol Myers Squibb's (BMY) Opdivo (nivolumab) and Keytruda are good immunotherapy drugs, however they sometimes lack execution. At least 60% of patients don’t respond to anti PD-1 therapies. That means there is plenty of room for a combination approach between OncoSec’s technology and Keytruda to help those who don’t respond to monotherapy alone (Keytruda or Opdivo alone). This is accomplished because IL-12 stimulates CD4+ and CD8+ T-cells that target and kill cancerous cells. In therapy with PD-1 drugs such as Keytruda alone some patients don’t generate the immune response necessary with T-cells to clear the tumor. IL-12 enhances the T-cell immune response, making therapy as a combination approach that much more superior.

1 2 3 4
View single page >> |

Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Mad About Money 3 years ago Member's comment

Terry Chrisomalis, I realize there's no such thing as a sure thing, but realistically speaking, if I purchased $ONCS, how long would it take to see that investment payoff? Should things go according to plan, of course.

Terry Chrisomalis 3 years ago Author's comment

within six months to a year. They will try to release preliminary results of the combo by the end of the 4Q 2017

Harry Goldstein 3 years ago Member's comment

I appreciate a promising investment that also helps people. Bullish on $ONCS and $MRK.

Joe Black 3 years ago Member's comment

Couldn't agree more. At the current price, I could buy $ONCS without breaking the bank too. That's a gamble I'm willing to take.

Terrence Howard 3 years ago Member's comment

This sounds very promising indeed.

My Stock Tips 3 years ago Member's comment

Thanks Terry Chrisomalis, I made some good money buying this stock after reading your article last week.

Johannas Kolan 3 years ago Member's comment

Is further pre-clinical research possible or not?

Alexis Renault 3 years ago Member's comment

Thanks for this info, Terry Chrisomalis. Is there any sort of official partnership or cooperation between #OncoSecMedical and #Merck to use ImmunoPulse IL-12 technology in conjunction with #Keytruda? $ONCS $MRK

Terry Chrisomalis 3 years ago Author's comment

No upfront payments yet or milestones. For now Merck is providing Keytruda to Oncosec. My bet though is that if the results are good not only can Oncosec file for accelerated approval, but Merck could either partner with them on commercial launch or maybe even buy the company. Again, that is pending positive and robust data from the PISCES trial.

Derek Snyder 3 years ago Member's comment

Good read, thanks.

Dick Kaplan 3 years ago Member's comment

Very impressed with the #OncosSec trial results. $ONCS $MRK $BMY

BreakingBad News 3 years ago Member's comment

More good news on the war against #Cancer, thanks. #Novartis also has made great progress against B-cell acute lymphoblastic leukemia: www.talkmarkets.com/.../finally-a-cure-for-cancer $ONCS $NVS

Bill Johnson 3 years ago Member's comment

$ONCS has been looking good today.